BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Nevola R, Acierno C, Pafundi PC, Adinolfi LE. Chronic hepatitis C infection induces cardiovascular disease and type 2 diabetes: mechanisms and management. Minerva Med 2021;112:188-200. [PMID: 33205641 DOI: 10.23736/S0026-4806.20.07129-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
Number Citing Articles
1 Sulima DL, Suleymanova SS, Yakovlev AA, Koryagin VN, Rassokhin VV. Virological failures of primary interferon-free therapy in patients with chronic HCV RNA viremia and successful repeated interferon-free therapy. VIČ-infekc immunosupr 2022;14:100-109. [DOI: 10.22328/2077-9828-2022-14-3-100-109] [Reference Citation Analysis]
2 Chi ZC. Progress in understanding of association between metabolic associated fatty liver disease and viral infectious diseases. Shijie Huaren Xiaohua Zazhi 2022; 30(18): 783-794 [DOI: 10.11569/wcjd.v30.i18.783] [Reference Citation Analysis]
3 Jiang Y, Zhou L. Association between chronic hepatitis C infection and metabolic syndrome: A meta-analysis. Nutrition Clinique et Métabolisme 2022. [DOI: 10.1016/j.nupar.2022.03.002] [Reference Citation Analysis]
4 Salama II, Raslan HM, Abdel-Latif GA, Salama SI, Sami SM, Shaaban FA, Abdelmohsen AM, Fouad WA. Impact of direct-acting antiviral regimens on hepatic and extrahepatic manifestations of hepatitis C virus infection. World J Hepatol 2022; 14(6): 1053-1073 [DOI: 10.4254/wjh.v14.i6.1053] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Matsumori A. Novel Biomarkers of Inflammation for the Management of Diabetes: Immunoglobulin-Free Light Chains. Biomedicines 2022;10:666. [DOI: 10.3390/biomedicines10030666] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
6 Ross AJ, Ross BJ, Lee OC, Hood HW, Sanchez FL, Sherman WF. Does Preoperative Antiviral Treatment for Hepatitis C Decrease Risk of Complications After Total Hip Arthroplasty? A Matched Cohort Study. J Arthroplasty 2022:S0883-5403(22)00253-4. [PMID: 35248753 DOI: 10.1016/j.arth.2022.02.102] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Mazzaro C, Quartuccio L, Adinolfi LE, Roccatello D, Pozzato G, Nevola R, Tonizzo M, Gitto S, Andreone P, Gattei V. A Review on Extrahepatic Manifestations of Chronic Hepatitis C Virus Infection and the Impact of Direct-Acting Antiviral Therapy. Viruses 2021;13:2249. [PMID: 34835054 DOI: 10.3390/v13112249] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
8 Siphepho PY, Liu YT, Shabangu CS, Huang JF, Huang CF, Yeh ML, Yu ML, Wang SC. The Impact of Steatosis on Chronic Hepatitis C Progression and Response to Antiviral Treatments. Biomedicines 2021;9:1491. [PMID: 34680608 DOI: 10.3390/biomedicines9101491] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
9 Roguljic H, Nincevic V, Bojanic K, Kuna L, Smolic R, Vcev A, Primorac D, Vceva A, Wu GY, Smolic M. Impact of DAA Treatment on Cardiovascular Disease Risk in Chronic HCV Infection: An Update. Front Pharmacol 2021;12:678546. [PMID: 34045969 DOI: 10.3389/fphar.2021.678546] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]